However, most patients are diagnosed with distant metastases, and the efficacy of traditional treatment modalities remains unsatisfactory.[2, 3] Among Asian populations, EGFR gene mutations are the most prevalent driver mutations in lung cancer, with mutation rates ranging from 30% to 50%.[4] EGFR‐TKIs are small‐molecule drugs that specifically target mutations in the EGFR gene. The gene discussed is EGFR; the disease is lung carcinoma.